Showing results (211-220 of 241) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.JCI Insight|April 20, 2017
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patientsVivek Subbiah, Muhammad Rizwan Khawaja, David S Hong, et al.Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.Journal for Immunotherapy of Cancer|June 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumorsMohamed H Derbala, Bettzy Stephen, Woochan Hwang, et al.NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.Cancer Discovery|November 30, 2018
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105Alexander Drilon, Siqing Fu, Manish R Patel, et al.Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.Pageof 25